LLY

1,103

-2.23%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

AZN

185.53

-0.15%↓

LLY

1,103

-2.23%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

AZN

185.53

-0.15%↓

LLY

1,103

-2.23%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

AZN

185.53

-0.15%↓

LLY

1,103

-2.23%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

AZN

185.53

-0.15%↓

LLY

1,103

-2.23%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

AZN

185.53

-0.15%↓

Home・Listă Acțiuni・Johnson and Johnson

Johnson and Johnson

Închisă

SectorSănătate

225.18 -2.6

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

224.96

Maxim

225.69

Indicatori cheie
By Trading Economics
Venit	119M 5.2B
Vânzări	-502M 24B
P/E Medie Sector	27.186 50.102
EPS	2.7
Randament dividend	2.24
Marjă de profit	21.756
Angajați	138,200
EBITDA	182M 6.4B

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+18.23% upside

Dividende
By Dow Jones
Randament dividend Medie Sector	2.24% 2.33%
Următoarele câștiguri	15 iul. 2026
Data viitoare de dividende	9 iun. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-9.4B 564B
Deschiderea anterioară	227.78
Închiderea anterioară	225.18

Sentimentul știrilor

By Acuity

46%

54%

116 / 344 Clasament în Healthcare

Johnson and Johnson Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 apr. 2026, 13:27 UTC

Achiziții, Fuziuni, Preluări

Johnson & Johnson to Acquire Atraverse Medical to Bolster Cardiac Device Portfolio

23 apr. 2026, 21:48 UTC

Achiziții, Fuziuni, Preluări

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

22 apr. 2026, 11:27 UTC

Câștiguri

Intuitive Surgical Earnings Show Big Beats Don't Always Spark Stock Rallies -- Barrons.com

14 apr. 2026, 19:38 UTC

Câștiguri

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 apr. 2026, 14:13 UTC

Câștiguri

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 apr. 2026, 12:57 UTC

Câștiguri

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 apr. 2026, 11:19 UTC

Câștiguri

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

14 apr. 2026, 10:34 UTC

Câștiguri

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

14 apr. 2026, 10:20 UTC

Market Talk

Câștiguri

J&J Sees Path to Double-Digit Growth by End of Decade -- Market Talk

14 apr. 2026, 10:20 UTC

Market Talk

Câștiguri

J&J's Tremfya Sales Continue to Surge -- Market Talk

14 apr. 2026, 10:20 UTC

Câștiguri

Johnson & Johnson: With MedTech, Anticipate Additional Rounds of VBP in China Throughout Year, Heavier in Second Half of Year >JNJ

14 apr. 2026, 10:20 UTC

Câștiguri

Johnson & Johnson: Expect Heavier Investment in First Half of 2026 Year >JNJ

14 apr. 2026, 10:20 UTC

Câștiguri

Johnson & Johnson: With Innovative Medicine, Expect More Pronounced Sales Impact From Newly Launched Products as 2026 Progresses>JNJ

14 apr. 2026, 10:20 UTC

Câștiguri

Johnson & Johnson Announce Planned Enterprise Business Review for Dec. 8, 2026 >JNJ

14 apr. 2026, 10:20 UTC

Câștiguri

Johnson & Johnson: Anticipate Higher EPS Growth in Second Half of Year Vs First Half >JNJ

14 apr. 2026, 10:20 UTC

Câștiguri

Johnson & Johnson: With MedTech, Expect Continued Acceleration of Newly Launched Products as Year Progresses With Normalized Seasonality >JNJ

14 apr. 2026, 10:20 UTC

Câștiguri

Johnson & Johnson: With MedTech, Surgery Transformation Sales Headwinds Expected to Increase Through Year >JNJ

14 apr. 2026, 10:20 UTC

Câștiguri

Johnson & Johnson Sees 2026 Adjusted Operational EPS $11.30-$11.50 Vs Prior View $11.28-$11.48 >JNJ

14 apr. 2026, 10:20 UTC

Câștiguri

Johnson & Johnson: Anticipate Fairly Consistent Operational Sales Growth in First and Second Half With 53rd Week Affecting Second Half >JNJ

14 apr. 2026, 10:20 UTC

Câștiguri

Johnson & Johnson: With Innovative Medicine, Anticipate Generic Competition for Opsumit (Second Half in U.S.) and Simponi (First Half in EU; Potentially Second Half in U. S.) >JNJ

14 apr. 2026, 10:20 UTC

Câștiguri

Johnson & Johnson Sees 2026 Adj. Operational Sales Growth in Range of 5.6%-6.6% Vs Prior View 5.4%-6.4% >JNJ

14 apr. 2026, 10:20 UTC

Câștiguri

Johnson & Johnson: 1Q Innovative Medicine Operational Sales Growth Driven Primarily by Darzalex, Carvykti, Erleada, Rybrevant/Lazcluze, Tremfya and Spravato >JNJ

14 apr. 2026, 10:20 UTC

Câștiguri

Johnson & Johnson Raises 2026 View To Sales $100.3B-$101.3B Vs Prior View $100B-$101B >JNJ

14 apr. 2026, 10:20 UTC

Câștiguri

Johnson & Johnson 1Q Orthopaedics Sales $2.38B >JNJ

14 apr. 2026, 10:20 UTC

Câștiguri

Johnson & Johnson: 1Q MedTech Business Growth Driven Primarily by Electrophysiology Products, Abiomed, Shockwave as Well as Trauma >JNJ

14 apr. 2026, 10:20 UTC

Câștiguri

Johnson & Johnson Sees 2026 Operational Sales of $99.7B-$100.7B Vs Prior View $99.5B-$100.5B>JNJ

14 apr. 2026, 10:20 UTC

Câștiguri

Johnson & Johnson 1Q Adj EPS $2.70 >JNJ

14 apr. 2026, 10:20 UTC

Câștiguri

Johnson & Johnson: New Treatment for Bladder Cancer Inlexzo Is Outperforming All Recent Launches Based on Unique Patients Treated in First 6 Months of Approval >JNJ

14 apr. 2026, 10:20 UTC

Câștiguri

Johnson & Johnson 1Q U.S. Sales $13.33B >JNJ

14 apr. 2026, 10:20 UTC

Câștiguri

Johnson & Johnson 1Q International Sales $10.73B >JNJ

Comparație

Modificare preț

Johnson and Johnson Așteptări

Obiectiv de preț

By TipRanks

18.23% sus

Prognoză pe 12 luni

Medie 266.4 USD 18.23%

Maxim 285 USD

Minim 250 USD

În baza a 17 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruJohnson and Johnson - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

17 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 17 analiști care au acordat evaluări ale acțiunilor Johnson and Johnson - Dist în ultimele 3 luni.

Sentiment

By Acuity

116 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.